Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get all the relevant market information you need — get it fast, on time, and accurately with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Incyte Corp (INCY)

Incyte Corp (INCY)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,718,682
  • Shares Outstanding, K 196,323
  • Annual Sales, $ 4,241 M
  • Annual Income, $ 32,610 K
  • EBIT $ 1,481 M
  • EBITDA $ 1,570 M
  • 60-Month Beta 0.81
  • Price/Sales 4.67
  • Price/Cash Flow 181.92
  • Price/Book 4.25

Options Overview Details

View History
  • Implied Volatility 38.87% (+3.40%)
  • Historical Volatility 32.74%
  • IV Percentile 54%
  • IV Rank 35.06%
  • IV High 64.77% on 10/31/25
  • IV Low 24.90% on 08/08/25
  • Expected Move (DTE 22) 6.14 (6.11%)
  • Put/Call Vol Ratio 1.99
  • Today's Volume 326
  • Volume Avg (30-Day) 2,154
  • Put/Call OI Ratio 0.96
  • Today's Open Interest 16,838
  • Open Int (30-Day) 47,548
  • Expected Range 94.30 to 106.58

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 25 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.66
  • Number of Estimates 8
  • High Estimate 1.83
  • Low Estimate 1.53
  • Prior Year 1.09
  • Growth Rate Est. (year over year) +52.29%

Price Performance

See More
Period Period Low Period High Performance
1-Month
93.54 +7.38%
on 12/12/25
107.61 -6.66%
on 11/25/25
-5.80 (-5.46%)
since 11/24/25
3-Month
81.09 +23.86%
on 09/25/25
109.28 -8.09%
on 11/12/25
+16.28 (+19.34%)
since 09/24/25
52-Week
53.56 +87.53%
on 04/09/25
109.28 -8.09%
on 11/12/25
+30.53 (+43.67%)
since 12/24/24

Most Recent Stories

More News
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma

Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi ® (tafasitamab) in combination with rituximab and lenalidomide...

INCY : 100.44 (-0.47%)
Incyte Japan Announces Approval of Zynyz® (retifanlimab) for the First-Line Treatment of Advanced Anal Cancer

Incyte Biosciences Japan G.K. today announced the Japan Ministry of Health, Labour and Welfare (MHLW) approval of Zynyz ® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based...

INCY : 100.44 (-0.47%)
Incyte to Present at Upcoming Investor Conference

Incyte (Nasdaq:INCY) announced today that it will present at the 44 th Annual J. P. Morgan Healthcare Conference on Monday, January 12, 2026 at 8:15 am (PST). The presentation...

INCY : 100.44 (-0.47%)
Incyte Announces European Commission Approval of Minjuvi® (tafasitamab) for the Treatment of Relapsed or Refractory Follicular Lymphoma

Minjuvi ® (tafasitamab) in combination with lenalidomide and rituximab is the first CD19- and CD20-dual-targeted immunotherapy combination regimen approved for eligible patients...

INCY : 100.44 (-0.47%)
Is Incyte Stock Outperforming the Nasdaq?

Despite Incyte’s outperformance relative to the Nasdaq Composite over the past year, Wall Street analysts remain cautiously optimistic about the stock’s prospects.

$NASX : 23,613.31 (+0.22%)
INCY : 100.44 (-0.47%)
EXEL : 46.51 (-0.21%)
Incyte Announces Change to its Board of Directors

Incyte (Nasdaq:INCY) today announced the resignation of Hervé Hoppenot from the Company’s Board of Directors, effective immediately. As previously announced, Mr. Hoppenot had been serving as an advisor...

INCY : 100.44 (-0.47%)
Incyte Presents Updated Positive Data at ASH 2025 Reinforcing the Potential of INCA033989, its First-in-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Essential Thrombocythemia

Nearly all (90%) of essential thrombocythemia (ET) patients treated with INCA033989 at the higher dose achieved a hematologic response (HR) with 83.3% achieving a complete HR ...

INCY : 100.44 (-0.47%)
Incyte Announces New Positive Data for INCA033989, its First-In-Class mutCALR-Targeted Monoclonal Antibody, in Patients with Myelofibrosis Presented at ASH 2025

Rapid and robust reductions in spleen volume and symptoms, and improvements in anemia were observed with INCA033989 as monotherapy and in combination with ruxolitinib (Jakafi ® )...

INCY : 100.44 (-0.47%)
Incyte’s First-in-Class mutCALR-Targeted Monoclonal Antibody, INCA033989, Granted Breakthrough Therapy Designation by U.S. FDA

The Company plans to initiate a Phase 3 program evaluating INCA033989 in essential thrombocythemia (ET) patients with all types of CALR mutations in mid-2026, following alignment with regulators ...

INCY : 100.44 (-0.47%)
Incyte Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Incyte Corporation (Nasdaq: INCY) announced today equity inducement awards grants to Richard Hoffman, Company’s new Executive Vice President and General Counsel, pursuant to the Company’s 2024 Inducement...

INCY : 100.44 (-0.47%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 96% Buy with a Average short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Incyte Corporation is a biopharmaceutical company focused on the discovery, development and commercialization of proprietary therapeutics. The company conducts its European clinical development operations in Geneva, Switzerland. Incyte's lead drug, Jakafi (ruxolitinib), is a first-in-class JAK1/JAK2...

See More

Key Turning Points

3rd Resistance Point 102.41
2nd Resistance Point 101.96
1st Resistance Point 101.20
Last Price 100.44
1st Support Level 99.99
2nd Support Level 99.54
3rd Support Level 98.78

See More

52-Week High 109.28
Last Price 100.44
Fibonacci 61.8% 87.99
Fibonacci 50% 81.42
Fibonacci 38.2% 74.84
52-Week Low 53.56

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar